CombinatoRx, Incorporated
CombinatoRx (NASD:CRXX) is a biopharmaceutical company pioneering a systems biology approach to create new combination medicines that attack diseases on multiple fronts. The Company has an impressive clinical and preclinical pipeline of novel agents, including a Phase I/II clinical program for cancer and two Phase I programs for rheumatoid arthritis. EHCP participated in the financing round preceding CombinatoRx's successful initial public offering in November 2005. Other investors in CombinatoRx include Boston Millennia Partners, Canaan Partners, Flagship Ventures, Global Life Science Ventures and TL Ventures, among others.